Exploring The Impact of Capecitabine Treatment on Hormonal and Biochemical Markers in Women with Breast Cancer

Authors

  • Raaid Fadhl Abbas Masoudi Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Karbala, Iraq
  • Ahmed Salih Sahib Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Karbala, Iraq
  • Hasanain Shakir Mahmood Department of Pharmaceutics, College of Pharmacy, University of Alkafeel, Najaf, Iraq & Department of Pharmaceutics, College of Pharmacy, University of Kerbala, Karbala, Iraq
  • Karar Kadhim Mohsin Imam Al_Hussein Hematology and Oncology Center, The Holy City of Karbala, Karbala, Iraq.
  • Ali Amal Aldeen Majeed sultan Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Karbala, Iraq

DOI:

https://doi.org/10.31351/vol32issSuppl.pp99-103

Keywords:

Ca 15.3 , Breast cancer, capecitabine, Estradiol, Calcium

Abstract

Cancer antigen 15-3 (CA15-3) is a widely used tumor marker, and the serum level of this tumor marker is measured periodically in breast cancer patients during the chemotherapy period by capecitabine , Assuming that the higher serum levels of this tumor marker can be a potential risk in breast cancer patients, the study aimed to examine the effect on  capecitabine with Ca15.3, serum estradiol, and calcium levels in postmenopausal women with breast cancer. The study was conducted on a total of 200 women, including 100 women without breast cancer who served as a control group aged range from (45-75years) and 100 women with breast cancer whose ages ranged from (40-70years). Patients at the oncology center at Imam al-Hussain medical city in Kerbala, Iraq, were sorted into groups based on their age, body mass index, disease duration, and treatment length for this study, which was done between July 2022 and October 2022, the efficacy of capecitabine, the plasma levels of (estradiol, Ca 15.3, and calcium) were measured in 100 breast cancer patients who had been taking the drug for at least 3 months. The findings revealed a statistically significant increase (p 0.05) in the concentration of Ca15.3 levels in women with breast cancer compared with control group, breast cancer (BC) is the most common form of cancer that results, and the average levels of serum calcium and estradiol were increased in patient had breast cancer chemotherapy and different with normal range, otherwise, the average level of serum calcium and estradiol in control groups within the normal range.in conclusion According to the ca15.3,serum calcium and estradiol levels, The high stability and existence of Ca15.3, serum calcium and estradiol in body serum make them a promising new diagnostic biomarker for breast cancer patients.

References

Anderson BO, Ilbawi AM, Fidarova E, Weiderpass E, Stevens L, Abdel-Wahab M, Mikkelsen B. The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases. The Lancet Oncology. 2021 May 1;22(5):578-81

Parkins KM, Dubois VP, Hamilton AM, Makela AV, Ronald JA, Foster PJ. Multimodality cellular and molecular imaging of concomitant tumour enhancement in a syngeneic mouse model of breast cancer metastasis. Scientific Reports. 2018 Jun 12;8(1):8930.

Abood RA, Abdahmed KA, Mazyed SS. Epidemiology of different types of cancers reported in Basra, Iraq. Sultan Qaboos University Medical Journal. 2020 Aug;20(3):e295.

Rasool R, Ullah I, Mubeen B, Alshehri S, Imam SS, Ghoneim MM, Alzarea SI, Al-Abbasi FA, Murtaza BN, Kazmi I, Nadeem MS. Theranostic Interpolation of Genomic Instability in Breast Cancer. International Journal of Molecular Sciences. 2022 Feb 7;23(3):1861.

Alqahtani S, Alzaidi R, Alsultan A, Asiri A, Asiri Y, Alsaleh K. Clinical pharmacokinetics of capecitabine and its metabolites in colorectal cancer patients. Saudi Pharmaceutical Journal. 2022 May 1;30(5):527-31.

Downloads

Published

2023-11-03

How to Cite

1.
Masoudi RFA, Ahmed Salih Sahib, Hasanain Shakir Mahmood, Karar Kadhim Mohsin, sultan AAAM. Exploring The Impact of Capecitabine Treatment on Hormonal and Biochemical Markers in Women with Breast Cancer . Iraqi Journal of Pharmaceutical Sciences [Internet]. 2023 Nov. 3 [cited 2024 Nov. 5];32(Suppl.):99-103. Available from: https://bijps.uobaghdad.edu.iq/index.php/bijps/article/view/2441